# Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

> **NCT06116890** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Kyowa Kirin Co., Ltd.** · enrollment: 180 (estimated)

## Conditions studied

- Neovascular Age-Related Macular Degeneration (nAMD)

## Interventions

- **DRUG:** KHK4951
- **DRUG:** Aflibercept Injection

## Key facts

- **NCT ID:** NCT06116890
- **Lead sponsor:** Kyowa Kirin Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-31
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-09-30
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2025-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06116890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06116890, "Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT06116890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*